Appointing new president no Botha for Aviro
This article was originally published in Scrip
Aviro Biopharmaceuticals, a contract development and manufacturing organisation servicing the pharmaceutical and medical devices industries, has appointed William Botha president. Mr Botha joins Aviro from Genzyme where he most recently served as senior director of operational excellence. Prior to that, he was a plant manager and director of pharmaceutical manufacturing at Baxter Healthcare.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.